Payment overview · 2025
General Payments
$624.32
22 reported records · 14 companies
Healthcare provider profile · identity verified
Robert J Megna, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FERRIS, TX · NPI 1407872039
Verified facts
What the public records show
CMS Open Payments records show Robert J Megna, D.O. received $624.32 in general payments during 2025 across 22 reported records.
HEARTFLOW, INC. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $140.46 | 22.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $92.25 | 14.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $84.07 | 13.5% | 4 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $58.99 | 9.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.88 | 7.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.91 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.83 | 4.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.66 | 4.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.87 | 3.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.86 | 3.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.76 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.87 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.06 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.85 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.32 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $140.46 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $92.25 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.13 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.94 | 3 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $58.99 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 148 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 810 | 253 |
| Ezetimibe | Ezetimibe | 700 | 225 |
| Amlodipine Besylate | Amlodipine Besylate | 666 | 203 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 130 |
| Losartan Potassium | Losartan Potassium | 342 | 118 |
| Lisinopril | Lisinopril | 319 | 102 |
| Carvedilol | Carvedilol | 310 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 103 |
| Metformin Hcl Er | Metformin Hcl | 285 | 92 |
| Indapamide | Indapamide | 211 | 68 |
| Ramipril | Ramipril | 199 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 59 |
| Gabapentin | Gabapentin | 166 | 58 |
| Jardiance | Empagliflozin | 148 | 38 |
| Potassium Chloride | Potassium Chloride | 147 | 52 |
| Omeprazole | Omeprazole | 143 | 44 |
| Tramadol Hcl | Tramadol Hcl | 141 | 38 |
| Repatha Sureclick | Evolocumab | 138 | 32 |
| Ozempic | Semaglutide | 135 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 36 |
| Metformin Hcl | Metformin Hcl | 131 | 46 |
| Allopurinol | Allopurinol | 124 | 36 |
| Vascepa | Icosapent Ethyl | 123 | 34 |
| Furosemide | Furosemide | 121 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 40 |
| Valsartan | Valsartan | 108 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 39 |
| Montelukast Sodium | Montelukast Sodium | 94 | 30 |
| Spironolactone | Spironolactone | 90 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 84 | 28 |
| Trazodone Hcl | Trazodone Hcl | 83 | 25 |
| Eliquis | Apixaban | 80 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 18 |
| Mounjaro | Tirzepatide | 77 | 13 |
| Xarelto | Rivaroxaban | 74 | 20 |
| Farxiga | Dapagliflozin Propanediol | 66 | 20 |
| Synthroid | Levothyroxine Sodium | 65 | 20 |
| Telmisartan | Telmisartan | 61 | 20 |
| Mupirocin | Mupirocin | 59 | 30 |
| Icosapent Ethyl | Icosapent Ethyl | 58 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 21 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 20 |
| Famotidine | Famotidine | 49 | 16 |
| Nitroglycerin | Nitroglycerin | 48 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 16 |
| Clonazepam | Clonazepam | 41 | 12 |
| Colchicine | Colchicine | 40 | 13 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 16 |
| Kerendia | Finerenone | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 27 | 11 |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Finasteride | Finasteride | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $624.32 · 22 records | HEARTFLOW, INC. | ENSITE, FFRct, Fluad, Flucelvax, GEMTESA, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, Mirena, REPATHA, TWIIST, VRAYLAR, VYNDAQEL | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error